Login / Register The Most Trusted Name in Medical Education

Urology

Improve your knowledge in the field of urology by taking one of Elsevier's complimentary continuing medical education courses.

138 17 287 JS 140x117

Immunotherapy: The Wave of the Future in Bladder Cancer?

Format: Supplement

This article reviews the role of immunotherapy in the treatment of locally advanced and metastatic urothelial cell carcinoma (UC). It describes the basic principles of cancer immunotherapy, as they relate to management of UC, and summarizes clinical data on current and investigational therapeutic approaches. Two immune checkpoint inhibitors are now approved for treatment of advanced UC in the United States, and the article discusses their unique response patterns and side effect profiles to help oncology clinicians appropriately incorporate these agents into patient care.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910692 116 x 140

ASCO GU 2017: A Therapeutic Update on the Management of Patients with Prostate Cancer

Format: Conference Reporter

Ground-breaking research on the molecular and genetic properties of prostate cancer (PC) was presented at the 2017 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO), held on February 16–18 in Orlando, Florida. This research provided many insights on the genetic changes associated with disease progression and the development of treatment resistance that may help inform treatment decisions for patients with PC in the near future. In this video presentation, three leading experts in the management of PC review key results presented at ASCO-GU 2017 and provide their thoughts on how the results may influence current research and practice.

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910668 116 x 140

ESMO 2016: A Therapeutic Update on Metastatic Castration Resistant Prostate Cancer

Format: Medical Meeting Reporter

Results from several key clinical trials evaluating new therapeutic approaches for patients with metastatic castration resistant prostate cancer were presented at the European Society for Medical Oncology (ESMO) 2016 Congress on October 7–11, 2016 in Copenhagen, Denmark. These results indicate that metastatic castration resistant prostate cancer is not a single disease and that biomarkers may play an essential role in deciding on best therapy for your patients. In this activity, you will listen to two leading experts in metastatic castration resistant prostate cancer management and research as they review the key data presented at ESMO 2016 and discuss the implications for current practice and future research.

Register »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
OA 125 x 125

ESMO 2016 Conference: Perspectives & Analysis: Breast Cancer, Lung Cancer and Non-Small Cell Lung Cancer

Format: Medical Meeting Reporter

Results from several key clinical trials evaluating therapeutic approaches for patients with metastatic breast cancer, metastatic castration resistant prostate cancer and non-small cell lung cancer were presented at the European Society for Medical Oncology (ESMO) 2016 Congress on October 7–11, 2016 in Copenhagen, Denmark. Participate in any of the following activities and hear leading experts in their respective fields discuss the implications for current practice and future research.

Take Courses »